TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15968653

Group type: EXPERIMENTAL
Intervention: Novel spectroscopic imaging method with high spectral and spatial resolution; improved sensitivity using a binomial 1 1 excitation pulse; narrow spectral bandwidth (6 ppm); measurement time acceptable.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post‐detection data processing scheme for correction of spectral artifacts.
Number of subjects: 0
Study: 12771603

Group type: EXPERIMENTAL
Intervention: Antithrombin III (Kybernin P)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11036377

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: Surgical teaching initiatives (TME concept workshops)
Number of subjects: 1406
Study: 8774196

Group type: EXPERIMENTAL
Intervention: Otolaryngology trainee assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anaesthetist assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined assessments
Number of subjects: 100
Study: 1316401

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LSD) with lactose capsules
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal-sodium diet (NSD) with salt capsules
Number of subjects: 20
Study: 3902954

Group type: EXPERIMENTAL
Intervention: Ultrasonography (U/S)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral cholecystography (OCG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Life table analysis (1 U/S)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Life table analysis (1 OCG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Life table analysis (2 successive U/S studies)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Life table analysis (1 U/S plus 1 OCG)
Number of subjects: 14
Study: 29888656

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2, 2 capsules daily containing 50×10^9 cfu of live organisms
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo, 2 capsules daily
Number of subjects: 113
Study: 26613768

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 324

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 324
Study: 23374652

Group type: EXPERIMENTAL
Intervention: PiCCO monitoring
Number of subjects: 708
Study: 21427425

Group type: COMPARATOR
Intervention: Continuous therapy (CT, n = 65)
Number of subjects: 156

Group type: COMPARATOR
Intervention: CD4‐guided cART (n = 91)
Number of subjects: 156
Study: 18834717

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 93

Group type: COMPARATOR
Intervention: Diet following 2003 American Diabetes Association guidelines
Number of subjects: 93
Study: 17555947

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 522

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 522
Study: 15234055

Group type: EXPERIMENTAL
Intervention: Ultrafractionated radiotherapy (0.5 Gy TDS: 4‐h gap)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (1.5 Gy/day)
Number of subjects: 8
Study: 11696466

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Non-naproxen NSAIDs
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 28000
Study: 9562293

Group type: COMPARATOR
Intervention: C (caffeine 5 mg x kg[-1])
Number of subjects: 8

Group type: COMPARATOR
Intervention: E (ephedrine 1 mg x kg[-1])
Number of subjects: 8

Group type: COMPARATOR
Intervention: C+E (caffeine and ephedrine combination)
Number of subjects: 8

Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 8

Group type: COMPARATOR
Intervention: C+E
Number of subjects: 8

Group type: COMPARATOR
Intervention: C
Number of subjects: 8

Group type: COMPARATOR
Intervention: C+E and C
Number of subjects: 8
Study: 7936513

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg/day for 14 days every 28 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 10 mg/day for 28 of 84 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 10 mg/day for 14 days every 84 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (all groups)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (less than monthly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (monthly)
Number of subjects: 80
Study: 2447257

Group type: EXPERIMENTAL
Intervention: Early high-dose phenobarbital treatment (15 mg/kg IV at 110 minutes, followed by 15 mg/kg after 4 hours, then 5 mg/kg every 24 hours for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early high-dose phenobarbital treatment
Number of subjects: 0
Study: 30335188

Group type: EXPERIMENTAL
Intervention: Survivorship Planning Consultation (SPC)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Time-controlled Wellness Rehabilitation Consultation (WRC)
Number of subjects: 198
Study: 26337539

Group type: EXPERIMENTAL
Intervention: Bi-weekly alternating ranibizumab/bevacizumab injections
Number of subjects: 18
Study: 25715991

Group type: EXPERIMENTAL
Intervention: Defibrillation testing
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No defibrillation testing
Number of subjects: 2500
Study: 23720852

Group type: EXPERIMENTAL
Intervention: Easyhaler (budesonide and formoterol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerolyser inhaler
Number of subjects: 0
Study: 21138462

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation (160 mg/day of oral testosterone undecanoate)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 18277833

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions with a motivational interviewing‐trained nurse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 0
Study: 21494076

Group type: EXPERIMENTAL
Intervention: Genetic polymorphism at codon 10 of the TGF‐β1 gene
Number of subjects: 301
Study: 15760313

Group type: EXPERIMENTAL
Intervention: Buscopan suppositories
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 200
Study: 11962564

Group type: EXPERIMENTAL
Intervention: Community education program (18-month, multicomponent)
Number of subjects: 44
Study: 9845395

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (ulcer-like dyspepsia)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (ulcer-like dyspepsia)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo (ulcer-like dyspepsia)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (reflux-like dyspepsia)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (reflux-like dyspepsia)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo (reflux-like dyspepsia)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 1262
Study: 7814301

Group type: EXPERIMENTAL
Intervention: Nilvadipine (16 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2910681

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucagon-(1-21)-peptide
Number of subjects: 20
Study: 22438

Group type: EXPERIMENTAL
Intervention: Glafenine (Glifanan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30572426

Group type: EXPERIMENTAL
Intervention: Intensive education on hand hygiene
Number of subjects: 6484

Group type: COMPARATOR
Intervention: General education (Control)
Number of subjects: 6484
Study: 27553181

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated patients from MorCAP)
Number of subjects: 0
Study: 23668849

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 23
Study: 22167077

Group type: EXPERIMENTAL
Intervention: Human milk mixed with a multinutrient fortifier
Number of subjects: 39

Group type: COMPARATOR
Intervention: Human milk alone (control)
Number of subjects: 39
Study: 20572865

Group type: EXPERIMENTAL
Intervention: Lingual brackets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buccal brackets
Number of subjects: 0
Study: 18549330

Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Number of subjects: 3
Study: 15994264

Group type: COMPARATOR
Intervention: Cisplatin-based chemotherapy + supportive care (C)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Supportive care alone (NoC)
Number of subjects: 194
Study: 12899545

Group type: EXPERIMENTAL
Intervention: ROBODOC femoral milling system
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional cementless THA surgery
Number of subjects: 71
Study: 10093002

Group type: EXPERIMENTAL
Intervention: CR2194 (spiroglumide) 1, 2.5 or 7.5 mg kg‐1 h‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CR2194 (7.5 mg kg‐1 h‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CR2194 (spiroglumide)
Number of subjects: 0
Study: 8604591

Group type: EXPERIMENTAL
Intervention: desferrioxamine B (100 mg/kg/day) as a single agent
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: desferrioxamine B in addition to standard quinine-based therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: placebo in addition to standard quinine-based therapy
Number of subjects: 158
Study: 1954075

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 18
Study: 7023799

Group type: EXPERIMENTAL
Intervention: Ionic contrast medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ionic contrast medium
Number of subjects: 0
Study: 30586757

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 29287876

Group type: EXPERIMENTAL
Intervention: Preoperative visiting operation room (PVOR)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine preoperative visit (RV)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Routine preoperative visit plus propofol (RP)
Number of subjects: 69
Study: 27809905

Group type: EXPERIMENTAL
Intervention: Peyton's four-step approach (PG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional teaching (CG)
Number of subjects: 95
Study: 25142002

Group type: EXPERIMENTAL
Intervention: ixmyelocel-T (administered intramyocardially via minithoracotomy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ixmyelocel-T (administered intramyocardially using the NOGA Myostar catheter)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 61
Study: 22896665

Group type: EXPERIMENTAL
Intervention: 600 mg BMS‐663068 plus 100 mg ritonavir every 12 hours (Q12H)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 plus 100 mg ritonavir every bedtime
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 plus 100 mg ritonavir Q12H
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 Q12H plus 100 mg ritonavir every morning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 Q12H
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 19747930

Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17591623

Group type: EXPERIMENTAL
Intervention: Blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results, in addition to usual care (n=150)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Blood glucose self monitoring with additional training of patients in interpretation and application of the results (n=151)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Standardised usual care with measurements of HbA1c every three months (n=152)
Number of subjects: 453
Study: 15642546

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 1080
Study: 12372673

Group type: EXPERIMENTAL
Intervention: IR-low (HOMA: 36.3 +/- 1.7)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IR-medium (HOMA: 62.6 +/- 1.6)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IR-high (HOMA: 123.1 +/- 12.8)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation between IR and hemodynamic measurements
Number of subjects: 75
Study: 12379064

Group type: EXPERIMENTAL
Intervention: Ximelagatran, 24 mg twice daily for 7 to 12 days
Number of subjects: 680

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.5, range 1.8 to 3.0), starting on the evening of the day of surgery
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 680

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 680
Study: 9822045

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2- to 0.4-mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cilazapril (2.5- to 5.0-mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cilazapril
Number of subjects: 14
Study: 8017470

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg once daily for 6 weeks, then 20 mg twice daily for an additional 6 weeks
Number of subjects: 66
Study: 2637069

Group type: EXPERIMENTAL
Intervention: Midazolam (short-acting benzodiazepine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pentazocin or Piritramid (analgesics)
Number of subjects: 12
Study: 334185

Group type: COMPARATOR
Intervention: 300 mg of aspirin
Number of subjects: 140

Group type: COMPARATOR
Intervention: 600 mg of aspirin
Number of subjects: 140

Group type: COMPARATOR
Intervention: 1200 mg of aspirin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 75 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 150 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 300 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140
Study: 31555976

Group type: EXPERIMENTAL
Intervention: Nutraceutical treatment (Omega‐3: EPA 1 g/DHA 656 mg, SAMe, zinc, 5‐HTP, folinic acid, and co‐factors)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 29490560

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise in an aquatic environment (1-hour sessions, 3 days a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary women (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise in an aquatic environment
Number of subjects: 0
Study: 27804048

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted Keraring ICRS (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MyoRing (Group B)
Number of subjects: 44
Study: 25705872

Group type: COMPARATOR
Intervention: 8 weeks nicotine patch treatment
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: 24 weeks nicotine patch treatment
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: 52 weeks nicotine patch treatment
Number of subjects: 525
Study: 23518148

Group type: EXPERIMENTAL
Intervention: Sunitinib therapy (2nd-line)
Number of subjects: 20
Study: 21460008

Group type: EXPERIMENTAL
Intervention: Pentavalent antimony treatment with early antihelminthic therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pentavalent antimony treatment with deferred antihelminthic therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall time to cure
Number of subjects: 90
Study: 19546250

Group type: EXPERIMENTAL
Intervention: Prasugrel active metabolite (Pras‐AM) in patients weighing <60 kg
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Prasugrel active metabolite (Pras‐AM) in patients >=75 years
Number of subjects: 1159
Study: 16469323

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) therapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 83
Study: 15598121

Group type: EXPERIMENTAL
Intervention: Naive users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Users with brief training or instructions
Number of subjects: 0
Study: 11594991

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 19

Group type: COMPARATOR
Intervention: 6‐0 vicryl
Number of subjects: 19
Study: 9182082

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil tablet form (250 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefuroxime axetil granule form (250 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (both forms)
Number of subjects: 12
Study: 8314425

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intensified treatment
Number of subjects: 85
Study: 2967185

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg o.d. for 4 weeks, then 20 mg o.d. for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Verapamil 80 mg t.i.d. for 4 weeks, then 120 mg t.i.d. for 4 weeks
Number of subjects: 26
Study: 31145031

Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention over a 1-year period
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1597

Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention in overweight or obese individuals (BMI ≥23 kg/m2)
Number of subjects: 1597

Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention in lean individuals (BMI <23 kg/m2)
Number of subjects: 1597
Study: 30309721

Group type: EXPERIMENTAL
Intervention: IV elesclomol plus weekly paclitaxel
Number of subjects: 58
Study: 26099162

Group type: EXPERIMENTAL
Intervention: Arthritis Foundation Tai Chi Program
Number of subjects: 343

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 343
Study: 24769437

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) each treatment day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Greater distribution of treatment (10 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CIMT (60 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22060159

Group type: EXPERIMENTAL
Intervention: Massage intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 20
Study: 20601897

Group type: EXPERIMENTAL
Intervention: Infliximab combined with methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study: 17640375

Group type: EXPERIMENTAL
Intervention: Sucrose (44% sucrose, 2 ml)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (sterile water, 2 ml)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control & Pacifier
Number of subjects: 84
Study: 16291712

Group type: EXPERIMENTAL
Intervention: Anidulafungin with placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Voriconazole with placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anidulafungin with voriconazole
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Voriconazole metabolite
Number of subjects: 17
Study: 12932114

Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA radioaerosol lung scintigraphy (inhalation of radiotracer for 5 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spirometric lung function test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Work duration correlation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy volunteers, n=10)
Number of subjects: 10
Study: 10655928

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 36
Study: 8664521

Group type: EXPERIMENTAL
Intervention: CyA and steroids (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CyA and Aza (group 2)
Number of subjects: 100
Study: 2057968

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 1212
Study: 6401365

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral gold (Auranofin)
Number of subjects: 0
Study: 3516041

Group type: EXPERIMENTAL
Intervention: Protocol C2-72
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Protocol D-74
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 92
Study: 31924332

Group type: EXPERIMENTAL
Intervention: T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m2 for 1.5 h, every 3 weeks)
Number of subjects: 576

Group type: COMPARATOR
Intervention: PLD (50 mg/m2 for 1.5 h, every 4 weeks)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: T + PLD (for patients with BRCA1/2 mutations)
Number of subjects: 576

Group type: COMPARATOR
Intervention: PLD (for patients with BRCA1/2 mutations)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: T + PLD (for patients with BRCA1/2 mutations and a 6-12 months platinum-free interval)
Number of subjects: 576

Group type: COMPARATOR
Intervention: PLD (for patients with BRCA1/2 mutations and a 6-12 months platinum-free interval)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: T + PLD
Number of subjects: 576

Group type: COMPARATOR
Intervention: PLD
Number of subjects: 576